Silexion Therapeutics regains compliance with Nasdaq listing requirements

Silexion Therapeutics (SLXN) announced that it has received written notification from The Nasdaq Stock Market confirming that the Company has regained compliance with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), concerning the minimum bid price and shareholders’ equity requirements. “We are pleased to have regained full compliance with Nasdaq’s listing requirements,” said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. “This milestone reinforces our strong financial foundation as we advance toward our planned Phase 2/3 clinical trials for SIL204 in the first half of 2026. With our recent preclinical data demonstrating up to 97% inhibition rates with activity across multiple KRAS-driven cancer types and our strategic CRO collaboration now in place, we remain focused on executing our clinical development strategy and working to deliver transformative RNAi therapies to patients with difficult-to-treat cancers.”